Page last updated: 2024-11-08

pimaric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pimaric acid: RN given refers to (D)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID220338
CHEMBL ID1410398
CHEBI ID39
SCHEMBL ID177983
MeSH IDM0053173
PubMed CID10086296
CHEMBL ID1735595
SCHEMBL ID14207398
MeSH IDM0053173

Synonyms (50)

Synonym
pimaric acid, d
nsc-2956
pimaric acid
nsc2956 ,
d-pimaric acid
.alpha.-pimaric acid
pimara-8(14),15-dien-19-oic acid
1-phenanthrenecarboxylic acid, 7-ethenyl-1,2,3,4,4a,4b,5,6,7,9,10,10a-dodecahydro-1,4a,7-trimethyl-, (1r,4ar,7s)-
(1r,4ar,4bs,7s,10ar)-1,4a,7-trimethyl-7-vinyl-3,4,4b,5,6,9,10,10a-octahydro-2h-phenanthrene-1-carboxylic acid
tnp00231
NCGC00017305-01
dextropimaric acid
C09159
127-27-5
(+)-pimaric acid
usic acid
13a-methyl-13-vinylpodocarp-8(14)-ene-15-oic acid
(1r,4ar,4bs,7s,10ar)-7-ethenyl-1,4a,7-trimethyl-3,4,4b,5,6,9,10,10a-octahydro-2h-phenanthrene-1-carboxylic acid
ST053518 ,
delta8(14)-pimaric acid
podocarp-8(14)-en-15-oic acid, 13alpha-methyl-13-vinyl-
unii-88r98z71ni
1-phenanthrenecarboxylic acid, 7-ethenyl-1,2,3,4,4a,4b,5,6,7,9,10,10a-dodecahydro-1,4a,7-trimethyl-, (1theta-(1alpha,4abeta,4balpha,7beta,10aalpha))-
88r98z71ni ,
1-phenanthrenecarboxylic acid, 7-ethenyl-1,2,3,4,4a,4b,5,6, 7,9,10,10a-dodecahydro-1,4a, 7-trimethyl-, (1r-(1alpha,4abeta,4balpha, 7beta,10aalpha))-
CHEMBL1410398
chebi:39 ,
pimaric acid [mi]
(1r,4ar,4bs,7s,10ar)-7-ethenyl-1,2,3,4,4a,4b,5,6,7,9,10,10a-dodecahydro-1,4a,7-trimethyl-1-phenanthrenecarboxylic acid
SCHEMBL177983
AKOS024282152
alpha-pimaricacid
DTXSID80858728
1,4a,7-trimethyl-7-vinyl-1,2,3,4,4a,4b,5,6,7,9,10,10a- dodecahydrophenanthrene-1-carboxylic acid
Q418035
CS-0023138
MS-24370
HY-N3063
MLS002473039
smr001397143
pimaradienoic acid
HMS2196A20
CHEMBL1735595
SCHEMBL14207398
AC-34117
HY-N6908
(1r,4as,4br,7r,10as)-7-ethenyl-1,4a,7-trimethyl-3,4,4b,5,6,9,10,10a-octahydro-2h-phenanthrene-1-carboxylic acid
CS-0100527
MS-24368
AKOS040760349

Research Excerpts

Overview

Pimaric acid is a naturally occurring resin. It has been found to perform many pharmacological activities including, anticancer activity.

ExcerptReferenceRelevance
"Pimaric acid is a naturally occurring resin and has been found to perform many pharmacological activities including, anticancer activity. "( Anticancer effects of Pimaric acid is mediated via endoplasmic reticulum stress, caspase-dependent apoptosis, cell cycle arrest, and inhibition of cell migration in human ovarian cancer cells.
Han, W; Li, W; Xuemei, G; Yajun, H; Yi, H; Yilin, Z; Zhongxiang, Z, 2022
)
2.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diterpenoidAny terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2C19 precursorHomo sapiens (human)Potency7.94330.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency6.30960.00636.904339.8107AID883
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency6.30960.00638.235039.8107AID883
ATAD5 protein, partialHomo sapiens (human)Potency14.57500.004110.890331.5287AID504467
Smad3Homo sapiens (human)Potency25.11890.00527.809829.0929AID588855
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency50.11876.309627.099079.4328AID602179
importin subunit beta-1 isoform 1Homo sapiens (human)Potency1.03235.804836.130665.1308AID540253
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency29.93490.168316.404067.0158AID720504
snurportin-1Homo sapiens (human)Potency1.03235.804836.130665.1308AID540253
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency89.12510.425612.059128.1838AID504891
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency1.03235.804816.996225.9290AID540253
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency44.66843.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (75)

Assay IDTitleYearJournalArticle
AID1246297Antiproliferative activity against human triple-negative MDA-MB-231 cells after 72 hrs by CellTiter-Glo assay2015European journal of medicinal chemistry, Sep-18, Volume: 102(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID713893Antimycobacterial activity against Mycobacterium tuberculosis2012European journal of medicinal chemistry, Mar, Volume: 49Recent advances in antitubercular natural products.
AID1356584Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay2018Journal of natural products, 08-24, Volume: 81, Issue:8
Structural Characterization of Terpenoids from Abies holophylla Using Computational and Statistical Methods and Their Biological Activities.
AID1152394Agonist activity at LXR-alpha (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 1 to 25 uM after 40 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1152397Activation of RAR in mouse F9 cells assessed as increase in CYP26A1 mRNA level at 10 uM after 48 hrs by RT-PCR analysis2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1152399Activation of RAR in mouse F9 cells assessed as increase in CYP26A1 mRNA level at 10 uM after 48 hrs by RT-PCR analysis in presence of RAR antagonist BMS4932014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1356585Cytotoxicity against mouse BV2 cells assessed as cell viability at 20 uM measured after 24 hrs by MTT assay relative to control2018Journal of natural products, 08-24, Volume: 81, Issue:8
Structural Characterization of Terpenoids from Abies holophylla Using Computational and Statistical Methods and Their Biological Activities.
AID1152393Agonist activity at PPARdelta (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 1 to 25 uM after 40 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1152392Agonist activity at PPARgamma (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 1 to 25 uM after 40 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1152400Induction of RAR-mediated differentiation of human HL60 cells at 1 uM after 4 days by NBT assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1152391Agonist activity at human RARalpha expressed in HEK293 cells assessed as transcriptional activation at 0.1 to 50 uM after 40 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1152395Activation of RAR in human HepG2 cells assessed as increase in CAR mRNA level at 10 uM after 24 hrs by RT-PCR analysis2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1171079Antinociceptive activity in Swiss mouse assessed as reduction of formalin-induced paw flinches at 10 mg/kg, po for 30 mins2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171082Antiinflammatory activity in Swiss mouse assessed as reduction of complete Freund's adjuvant-induced licking at 10 mg/kg, po for 30 mins2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171096Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 1 hrs of treatment in presence of 0.3 mg/kg ODQ soluble guanylyl cyclase inhibitor2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171109Toxicity in Swiss mouse assessed as gastric MPO activity at 10 mg/kg, po daily for 7 days2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171095Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 5 hrs of treatment in presence of 90 mg/kg, ip L-NAME NOS inhibitor2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171112Toxicity in Swiss mouse assessed as DNA damage up to 40 mg/kg, po2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171106Hepatotoxicity in Swiss mouse assessed as plasma ALT level at 10 mg/kg, po daily for 7 days2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171105Hepatotoxicity in Swiss mouse assessed as plasma AST level at 10 mg/kg, po daily for 7 days2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1152390Agonist activity at human RXRalpha expressed in HEK293 cells assessed as transcriptional activation up to 100 uM after 40 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1171097Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 3 hrs of treatment in presence of 0.3 mg/kg ODQ soluble guanylyl cyclase inhibitor2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171104Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 5 hrs of treatment in presence of 0.3 mg/kg glybenclamide ATP-sensitive potassium 2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1152401Induction of RAR-mediated differentiation of human HL60 cells at 1 to 25 uM after 4 days by NBT assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1171100Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 3 hrs of treatment in presence of 0.5 ug KT5823 inhibitor of PKG2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171087Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced TNFalpha production in cutaneous plantar tissue at 10 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs of treatment2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1152392Agonist activity at PPARgamma (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 1 to 25 uM after 40 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1152394Agonist activity at LXR-alpha (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 1 to 25 uM after 40 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1171089Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced IL-33 production in cutaneous plantar tissue at 10 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs of treatment2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171102Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 1 hrs of treatment in presence of 0.3 mg/kg glybenclamide ATP-sensitive potassium 2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171080Antinociceptive activity in Swiss mouse assessed as reduction of formalin-induced licking at 10 mg/kg, po for 30 mins2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1152397Activation of RAR in mouse F9 cells assessed as increase in CYP26A1 mRNA level at 10 uM after 48 hrs by RT-PCR analysis2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1152389Agonist activity at human RARalpha expressed in HEK293 cells assessed as transcriptional activation at 1 to 100 uM after 40 hrs by luciferase reporter gene assay in presence of RAR antagonist LE1352014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1171116Analgesic activity in Swiss mouse assessed as effect on thermal threshold at 10 mg/kg, po by hot plate test2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID766739Antispasmodic activity in rat aorta assessed as inhibition of phenylephrine-induced aorta contraction at 100 uM after 60 mins relative to control2013Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18
Biotransformation of ent-pimaradienoic acid by cell cultures of Aspergillus niger.
AID1171111Toxicity in Swiss mouse assessed as micronuclei formation up to 40 mg/kg, po2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171083Antinociceptive activity in po dosed Swiss mouse assessed as inhibition of carrageenan-induced mechanical hyperalgesia up to 5 hrs2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1152395Activation of RAR in human HepG2 cells assessed as increase in CAR mRNA level at 10 uM after 24 hrs by RT-PCR analysis2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1171084Antinociceptive activity in Swiss mouse assessed as inhibition of carrageenan-induced mechanical hyperalgesia at 1 mg/kg, po after 1 hr2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171115Toxicity in Swiss mouse assessed as sedative effect at 10 mg/kg, po measured after 1 to 5.5 hrs of treatment by rota-rod test2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171078Analgesic activity in Swiss mouse assessed as reduction of acetic acid-induced abnormal writhing at 10 mg/kg, sc pretreated 30 mins before acetic acid challenge measured for 20 mins2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171099Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 1 hrs of treatment in presence of 0.5 ug KT5823 inhibitor of PKG2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171081Antiinflammatory activity in Swiss mouse assessed as reduction of complete Freund's adjuvant-induced paw flinches at 10 mg/kg, po for 30 mins2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171092Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 3 hrs of treatment2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171086Antinociceptive activity in Swiss mouse assessed as inhibition of complete Freund's adjuvant-induced mechanical hyperalgesia at 10 mg/kg, po daily after 24 hrs of CFA challenge measured after 3 hrs of treatment2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171098Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 5 hrs of treatment in presence of 0.3 mg/kg ODQ soluble guanylyl cyclase inhibitor2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171091Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced NFkappaB activation in cutaneous plantar tissue at 10 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs of treatment2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1152393Agonist activity at PPARdelta (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 1 to 25 uM after 40 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1171094Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 3 hrs of treatment in presence of 90 mg/kg, ip L-NAME NOS inhibitor2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171085Antinociceptive activity in Swiss mouse assessed as inhibition of carrageenan-induced mechanical hyperalgesia at 1 mg/kg, po after 5 hrs2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171088Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced IL-1beta production in cutaneous plantar tissue at 10 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs of treatment2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171103Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 3 hrs of treatment in presence of 0.3 mg/kg glybenclamide ATP-sensitive potassium 2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171076Analgesic activity in Swiss mouse assessed as reduction of acetic acid-induced abnormal writhing at 10 mg/kg, po pretreated 30 mins before acetic acid challenge measured for 20 mins2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1152388Agonist activity at human RARalpha expressed in HEK293 cells assessed as transcriptional activation at 1 to 100 uM after 40 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1171090Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced IL-10 production in cutaneous plantar tissue at 10 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs of treatment2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171077Analgesic activity in Swiss mouse assessed as reduction of acetic acid-induced abnormal writhing at 10 mg/kg, ip pretreated 30 mins before acetic acid challenge measured for 20 mins2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171113Antinociceptive activity in Swiss mouse assessed as inhibition of inflammation-induced nociceptive threshold at 10 mg/kg, po measured after 1 to 5.5 hrs of treatment by rota-rod test2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1152391Agonist activity at human RARalpha expressed in HEK293 cells assessed as transcriptional activation at 0.1 to 50 uM after 40 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1171093Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 1 hrs of treatment in presence of 90 mg/kg, ip L-NAME NOS inhibitor2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1152399Activation of RAR in mouse F9 cells assessed as increase in CYP26A1 mRNA level at 10 uM after 48 hrs by RT-PCR analysis in presence of RAR antagonist BMS4932014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Retinoic acid receptor agonist activity of naturally occurring diterpenes.
AID1171101Antinociceptive activity in Swiss mouse assessed as inhibition of PGE2-induced mechanical hyperalgesia at 10 mg/kg, po treated after 24 hrs of PGE2 challenge measured after 5 hrs of treatment in presence of 0.5 ug KT5823 inhibitor of PKG2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1171114Toxicity in Swiss mouse assessed as muscle relaxing at 10 mg/kg, po measured after 1 to 5.5 hrs of treatment by rota-rod test2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (4.76)18.7374
1990's2 (4.76)18.2507
2000's11 (26.19)29.6817
2010's23 (54.76)24.3611
2020's4 (9.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.20 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (2.63%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other37 (97.37%)84.16%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]